Researchers at Bar-Ilan University have unveiled a technology that promises to improve cancer treatment decisions based on a patient's biopsy. The pioneering biological research and development measures changes in immune system cells…
Currently patients with a form of the disease which has spread to one or two other parts of the body are assumed to be resistant to milder hormone therapy drugs
Patient-generated "passive data," collected from smartphones, offers an alternative – continuous, real-time insights into the health and behavior of those living with ...
Johnson & Johnson's results in treating bladder and prostate cancer. Learn about TAR-210's efficacy in high-risk NMIBC patients and TAR-200's promising outcomes for BCG-unresponsive cases.
Researchers at the University of Kentucky College of Nursing and DanceBlue Kentucky Children's Hospital Hematology/Oncology Clinic found that receiving financial and legal navigation services improves levels of financial toxicity and…
In an editorial, published in Oncoscience, researcher Rafael Parra-Medina from Fundación Universitaria de Ciencias de la Salud and Instituto Nacional de Cancerología discusses Latin America's (LA) population—a heterogeneous mix of…
Glioblastoma is an often fatal form of brain cancer, with only 5% of patients surviving beyond five years. The cancer is difficult to treat and almost always becomes resistant to treatment. As a result, recurrence of glioblastoma is…
Paul Carroll said he came back from Canada ‘with assurances’ from hospital management but now has no alternative but to move to Sligo for family reasons
The pioneering biological research and development measures changes in immune system cells adjacent to cancer cells, providing crucial insights into the patient's immune response and potentially enhancing the effectiveness of immunotherapy.
(MedPage Today) -- SAN ANTONIO -- Extended compared with standard lymphadenectomy at the time of radical cystectomy provided no survival benefit to patients with muscle-invasive bladder cancer (MIBC), according to a phase III trial.
Watchdogs last week gave the green light for pembrolizumab after studies suggested patients with Hodgkin's lymphoma on it lived longer than those given radiotherapy and chemotherapy.
(MedPage Today) -- SAN ANTONIO -- More than 70% of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) achieved complete responses to a novel gene therapy, a small preliminary trial showed.
Cancer patients in Scotland are being diagnosed more speedily - and treated sooner - thanks to a ground-breaking project using artificial intelligence (AI).
Insurance expansions under the Affordable Care Act (ACA) were linked with an increase in patients receiving care at accredited cancer hospitals in Pennsylvania, according to a study published in Health Services Research by University of…
A new editorial paper was published in Oncoscience (Volume 11) on April 22, 2024, entitled, "Exploring oncogenic driver molecular alterations in Hispanic/Latin American cancer patients: A call for enhanced molecular understanding."
Targeting anti-cancer therapy to affect cancer cells but not healthy cells is challenging. For chimeric antigen receptor (CAR) T–cell immunotherapy, where a patient's own immune cells are re-engineered to attack cancer cells, many solid…
Researchers at the UAB and the Hospital del Mar Research Institute have confirmed that patients with the presence of NK lymphocytes around tumors have a better response to treatment. This confirms the feasibility of using cytokines…
A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without compromising their safety, according to results of a phase two clinical trial…